Simon Rule, MD, PhD, a professor of hematology at Plymouth University Medical School in the United Kingdom, shares his treatment considerations for select patients with mantle cell lymphoma (MCL).
Rule says that in patients who are young and asymptomatic, his recommended approach is to watch and wait. This approach does not disadvantage the patient, Rule says. He mentions 1 patient in his early 50s that remained untreated for MCL with nodal disease for 12 years.
For patients with a P53 mutation, his suggestion is to try a more aggressive strategy, as it will be hard to get them into remission. In these patients, neither autograft or ibrutinib (Imbruvica) will work, so an early allogeneic stem cell transplant may be a good option.
For other patients with MCL, Rule says that physicians should use their preferred high-dose cytarabine with rituximab (Rituxan) maintenance.
For more resources and information regarding anticancer targeted therapies in mantle cell lymphoma: [ Ссылка ]
![](https://i.ytimg.com/vi/C_fz1uN58fw/maxresdefault.jpg)